

## Publications for Hamish Campbell

### 2018

Campbell, H., Fleming, N., Roth, I., Mehta, S., Wiles, A., Williams, G., Vennin, C., Arsic, N., Parkin, A., Pajic, M., Reddel, R., Braithwaite, A., et al (2018). delta133p53 isoform promotes tumour invasion and metastasis via interleukin-6 activation of JAK-STAT and RhoA-ROCK signalling. *Nature Communications*, 9, 1-13. <a href="http://dx.doi.org/10.1038/s41467-017-02408-0">[More Information]</a>

### 2016

Mehta, S., Tsai, P., Lasham, A., Campbell, H., Reddel, R., Braithwaite, A., Print, C. (2016). A study of TP53 RNA splicing illustrates pitfalls of RNA-seq methodology. *Advances in Cancer Research*, 76(24), 7151-7159. <a href="http://dx.doi.org/10.1158/0008-5472.CAN-16-1624">[More Information]</a>

Slatter, T., Wilson, M., Tang, C., Campbell, H., Ward, V., Young, V., Van Ly, D., Fleming, N., Braithwaite, A., Baird, M. (2016). Antitumor cytotoxicity induced by bone-marrow-derived antigen-presenting cells is facilitated by the tumor suppressor protein p53 via regulation of IL-12. *OncImmunology*, 5(3), 1-14. <a href="http://dx.doi.org/10.1080/2162402X.2015.1112941">[More Information]</a>

Roth, I., Campbell, H., Rubio, C., Vennin, C., Wilson, M., Wiles, A., Williams, G., Woolley, A., Timpson, P., Berridge, M., Braithwaite, A., et al (2016). The (delta)133p53 isoform and its mouse analogue (delta)122p53 promote invasion and metastasis involving pro-inflammatory molecules interleukin-6 and CCL2. *Oncogene*, 35(38), 4981-4989. <a href="http://dx.doi.org/10.1038/onc.2016.45">[More Information]</a>

### 2015

Slatter, T., Hung, N., Bowie, S., Campbell, H., Rubio, C., Speidel, D., Wilson, M., Baird, M., Royds, J., Braithwaite, A. (2015). (delta)122p53, a mouse model of (delta)133p53a enhances the tumor-suppressor activities of an attenuated p53 mutant. *Cell Death and Disease*, 6, 1-9. <a href="http://dx.doi.org/10.1038/cddis.2015.149">[More Information]</a>

### 2013

Campbell, H., Mehta, R., Neumann, A., Rubio, C., Baird, M., Slatter, T., Braithwaite, A. (2013). Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD). *Oncogene*, 32(7), 827-836. <a href="http://dx.doi.org/10.1038/onc.2012.102">[More Information]</a>

### 2012

Campbell, H., Slatter, T., Jeffs, A., Mehta, R., Rubio, C., Baird, M., Braithwaite, A. (2012). Does (Delta)133p53 isoform trigger inflammation and autoimmunity? *Cell Cycle*, 11(3), 446-450. <a href="http://dx.doi.org/10.4161/cc.11.3.19054">[More Information]</a>

Huschtscha-Holliday, L., Napier, C., Noble, J., Bower, K., Au, A., Campbell, H., Braithwaite, A., Reddel, R. (2012). Enhanced isolation of fibroblasts from human skin explants.

*BioTechniques*, 53(4), 239-244. <a href="http://dx.doi.org/10.2144/0000113939">[More Information]</a>

### 2011

Slatter, T., Hung, N., Campbell, H., Rubio, C., Mehta, R., Renshaw, P., Williams, G., Wilson, M., Engelmann, A., Jeffs, A., Braithwaite, A., et al (2011). Hyperproliferation, cancer, and inflammation in mice expressing a delta133p53-like isoform. *Blood*, 117(19), 5166-5177. <a href="http://dx.doi.org/10.1182/blood-2010-11-321851">[More Information]</a>

### 2009

Huschtscha-Holliday, L., Moore, J., Noble, J., Campbell, H., Royds, J., Braithwaite, A., Reddel, R. (2009). Normal human mammary epithelial cells proliferate rapidly in the presence of elevated levels of the tumor suppressors p53 and p21WAF1/CIP1. *Journal of Cell Science*, 122(16), 2989-2995. <a href="http://dx.doi.org/10.1242/jcs.044107">[More Information]</a>

### 2008

Chen, Y., Campbell, H., Wiles, A., Eccles, M., Reddel, R., Braithwaite, A., Royds, J. (2008). PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. *Cancer Research*, 68(14), 5724-5732. <a href="http://dx.doi.org/10.1158/0008-5472.CAN-08-0058">[More Information]</a>